GlassScriptPhysician profile
Greg F Powell
NPI 1184623829
$6,567.62
in general payments reported to CMS, 2019-2025
35 companies · $1,157 in 2025
The $1,157 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,376 · 2022: $767 · 2023: $1,293 · 2024: $1,975 · 2025: $1,157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,713 · Travel and Lodging: $667 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,712.63 |
| Travel and Lodging | $666.74 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,235.79 | 2021-2025 | |
| Boston Scientific Corporation | $1,013.27 | 2024 | Intracept |
| Biohaven Pharmaceuticals, INC. | $827.68 | 2021 | |
| Collegium Pharmaceutical, INC. | $678.03 | 2021-2025 | Belbuca, Xtampza, Nucynta |
| Medtronic, INC. | $497.10 | 2023-2025 | Intellis Adaptivestim, Synchromedii |
| Pfizer INC. | $287.36 | 2021-2025 | |
| Lundbeck LLC | $249.87 | 2022-2025 | Vyepti |
| Axsome Therapeutics, INC. | $229.14 | 2023-2025 | Sunosi, Symbravo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $207.44 | 2022-2025 | Relistor |
| Indivior INC. | $161.11 | 2022-2025 | Sublocade |
| Amgen INC. | $137.90 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $122.70 | 2022-2023 | Ztlido |
| Idorsia Pharmaceuticals US INC | $114.65 | 2023-2024 | Quviviq |
| Azurity Pharmaceuticals, INC. | $100.62 | 2023-2025 | Horizant, Horizant |
| Braeburn INC. | $95.47 | 2023-2025 | Brixadi |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $77.22 | 2021-2022 | |
| Allergan, INC. | $67.88 | 2021 | |
| Biodelivery Sciences International, INC. | $49.99 | 2021 | |
| Merck Sharp & Dohme LLC | $45.84 | 2021-2023 | Belsomra |
| Globus Medical, INC. | $34.19 | 2025 | Senza |
| Almatica Pharma LLC | $32.31 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.30 | 2022 | |
| Lilly USA, LLC | $29.15 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $28.01 | 2022-2025 | Euflexxa |
| Arbor Pharmaceuticals, INC. | $26.67 | 2022 | |
| Merz Pharmaceuticals, LLC | $24.93 | 2025 | Xeomin |
| Spr Therapeutics, INC | $23.34 | 2025 | Sprint Pns System |
| Abbott Laboratories | $20.41 | 2025 | Eterna |
| Horizon Therapeutics Plc | $20.14 | 2022 | |
| Eisai INC. | $19.48 | 2021 | |
| Radius Health, INC. | $18.27 | 2024 | Tymlos |
| Vertex Pharmaceuticals Incorporated | $16.63 | 2025 | |
| Impel Pharmaceuticals INC. | $15.84 | 2022 | |
| Virtus Pharmaceuticals LLC | $15.21 | 2021 | |
| Si-Bone, INC. | $14.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Greg Powell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.